



COMPANY CONTACT:

Endologix, Inc.
Paul McCormick
President and CEO
(949) 595-7200
www.endologix.com

INVESTOR CONTACTS:

Lippert/Heilshorn & Associates, Inc.
Bruce Voss (bvoss@lhai.com)
Jody Cain (jcain@lhai.com)
(310) 691-7100
www.lhai.com

**ENDOLOGIX ANNOUNCES 2007 SECOND QUARTER
FINANCIAL RESULTS CONFERENCE CALL**

Irvine, Calif. – July 20, 2007 – Endologix, Inc. (Nasdaq: ELGX), the developer of the Powerlink® System for the minimally invasive treatment of abdominal aortic aneurysms (AAA), today announced that the Company will hold a conference call to discuss 2007 second quarter financial results on Thursday, July 26, 2007, at 5:00 p.m. Eastern time (2:00 p.m. Pacific time).

Individuals interested in listening to the live conference call may do so by dialing (888) 463-4487 toll free within the U.S. and Canada, or (706) 634-5615 for international callers. A telephone replay of the conference call will be available for 48 hours beginning July 26 within two hours after the conclusion of the call, by dialing (800) 642-1687 domestically or (706) 645-9291 internationally, and entering reservation number 7242145.

The conference call can be heard live via audio webcast at the Company's Web site: www.endologix.com. Please go to the Interviews/Presentations page on the Investor Relations section of the Web site. A replay will also be available for 14 days.

About Endologix

Endologix, Inc. develops and manufactures minimally invasive treatments for vascular diseases. Endologix's Powerlink System is an endoluminal stent graft (ELG) for treating abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it the thirteenth leading cause of death in the U.S. In October 2004, Endologix received approval to market the Powerlink in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.

###